HemaQuest Pharma Raises $12 Million

HemaQuest Pharmaceuticals, a Newton, Mass.-based developer of small-molecule therapeutics to treat serious blood disorders, has raised $12 million in Series B funding. Aberdare Ventures led the round, and was joined by return backers De Novo Ventures, Forward Ventures and Lilly Ventures. HemaQuest previously raised $20 million.

North AmericaUSBriefs